Clinical trials: Gefitinib
Brain Neoplasms, Non Small Cell Lung Cancer
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
- Trial name
- NCT00234442
- Testing
- Iressa (Gefitinib)
- Where
- 4 sites in Italy
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Lung Cancer
Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
- Trial name
- NCT01130961
- Where
- Thailand
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Breast Neoplasms
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
- Trial name
- NCT00229697
- Testing
- Gefitinib, Tamoxifen
- Where
- 55 sites in United States, Argentina and 10 more
- Volunteers
- 317 people
- Sponsor
- AstraZeneca
Locally Advanced Prostate Cancer
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate…
- Trial name
- NCT00319787
- Testing
- Iressa
- Where
- 3 sites in Norway
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Breast Cancer
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.
- Trial name
- NCT00239343
- Testing
- gefitinib
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 160 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by…
- Trial name
- SELINE (NCT00608868)
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Neoplasms, Squamous Cell
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms…
- Trial name
- NCT00229723
- Testing
- gefitinib (Iressa), cisplatin, radiotherapy
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Colorectal Cancer
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in…
- Trial name
- NCT00234429
- Testing
- Gefitinib, raltitrexed
- Where
- 9 sites in Spain
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
NSCLC
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm, multicenter, phase II study
- Trial name
- NCT02976116
- Testing
- Fruquintinib, Gefitinib
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Hutchison Medipharma Limited
Carcinoma, Non-Small-Cell Lung
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung…
- Trial name
- NCT02088112
- Testing
- Gefitinib, MEDI4736
- Where
- 7 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Non-Small-Cell Lung Carcinoma
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
The purpose of this study is to observe an improvement in overall response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response.
- Trial name
- NCT01167244
- Testing
- BMS-690514
- Where
- 4 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Carcinoma
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung…
- Trial name
- NCT02039674
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
The primary objective of this trial is to identify the Maximum Tolerated Dose of BIBW 2992 therapy when given continuously in combination with Sirolimus.
- Trial name
- NCT00993499
- Testing
- BIBW 2992, Sirolimus (rapamycin)
- Where
- 8 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Boehringer Ingelheim
Non-small-cell Lung Cancer
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
This is an open-label, multicenter, randomized, phase II clinical trial, which aims to evaluate the effectiveness and safety of gefitinib versus combination of gefitinib and doublet chemotherapy or apatinib in advanced non-small…
- Trial name
- NCT03267654
- Testing
- gefitinib combined with chemotherapy, gefitinib combined with apatinib, gefitinib single agent
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Iressa 2nd Line Phase III Study in Japan
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety…
- Trial name
- NCT00252707
- Testing
- Gefitinib or Docetaxel
- Where
- 40 sites in Japan
- Volunteers
- 484 people
- Sponsor
- AstraZeneca
Squamous Cell Cancer, Cancer of Head and Neck
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination
- Trial name
- NCT00255476
- Testing
- gefitinib, cisplatin, 5-flourouracil
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or…
- Trial name
- NCT00234468
- Testing
- Iressa (Gefitinib)
- Where
- 32 sites in Italy
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas.
- Trial name
- NCT00228488
- Testing
- Gefitinib
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
- Trial name
- NCT00298688
- Testing
- Gefitinib
- Where
- 3 sites in Denmark, United Kingdom
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Pulmonary Cancer
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
- Trial name
- NCT00344773
- Testing
- Gefitinib
- Where
- 2 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- AstraZeneca